Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2023, representing a 20% year-over-year growth[5]. - The company reported a net profit of 500 million, representing a 20% increase year-over-year[59]. - The company reported a net profit margin of 15%, reflecting improved operational efficiency[5]. - The total assets of the company increased to 3 billion, a 10% rise from the previous year[5]. - The company expects revenue growth of 10% for the next quarter, projecting total revenue of 1.1 billion[59]. User Engagement - User data showed an increase in active users, reaching 10 million, which is a 15% increase compared to the previous period[5]. - User data showed a growth of 15% in active users, reaching a total of 2 million[59]. Future Guidance - The company provided guidance for the second half of 2023, expecting revenue to grow by an additional 25%[5]. - Future guidance indicates a focus on sustainable practices, aiming for a 25% reduction in carbon footprint by 2025[59]. Product Development - New product launches are anticipated, including a health monitoring device expected to generate 200 million in revenue within the first year[5]. - New product launches include a healthcare management platform expected to generate 200 million in revenue within the first year[59]. - The company is investing in new technology development, allocating 50 million towards R&D for innovative healthcare solutions[5]. - The company is investing 50 million in R&D for new technologies aimed at improving service efficiency[59]. Market Expansion - Market expansion plans include entering three new international markets by the end of 2023, aiming for a 10% market share in each[5]. - Market expansion plans include entering three new regions, projected to increase market share by 5%[59]. Strategic Acquisitions - The company is considering strategic acquisitions to enhance its service offerings, with a budget of 300 million earmarked for potential targets[5]. - The company completed an acquisition of a competitor for 300 million, expected to enhance product offerings[59]. Digital Marketing Strategy - The company plans to enhance its digital marketing strategy, aiming for a 30% increase in online engagement by the end of 2023[5]. - A new strategy focusing on digital marketing is anticipated to boost customer engagement by 30%[59]. Financial Management - The company employs a perpetual inventory system for its stocktaking[64]. - The company recognizes contract assets using a simplified method for measuring loss provisions[65]. - The company capitalizes development expenditures that meet certain criteria, transferring them to intangible assets upon reaching intended use[84]. - The company confirms liabilities for obligations to transfer goods or services to customers as contract liabilities[90]. - The company assesses the useful life and amortization methods of finite-lived intangible assets at each reporting period[63]. - The company recognizes employee compensation, including short-term and long-term benefits, as liabilities[91]. - The company measures financial liabilities at amortized cost using the effective interest method after initial recognition[75]. - The company adjusts the carrying amount of equity investments when significant influence is obtained, based on fair value and additional investment costs[71]. - The company recognizes impairment losses for non-current assets held for sale when their carrying amount exceeds fair value less costs to sell[67]. - The company evaluates expected liabilities based on reliable measurement of obligations and considers risks and uncertainties[96]. Revenue Recognition - The company recognizes revenue when the customer obtains control of the related goods or services, which is when the company has fulfilled its performance obligations[102]. - Revenue is confirmed based on the progress of performance obligations, using either the output method or input method, depending on the nature of the goods or services[103]. - Revenue from system platform construction is recognized upon project completion and customer acceptance[104]. Government Grants and Taxation - Government grants received are classified into asset-related and income-related grants, with the former used for acquiring or constructing long-term assets[106][127]. - Income-related government grants are recognized as deferred income if they are intended to compensate for future expenses or losses[129]. - The company has a tax rate of 15% for corporate income tax, applicable for the years 2021, 2022, and 2023[143]. - The company received a high-tech enterprise certificate valid for three years, allowing it to benefit from a reduced corporate income tax rate of 15%[143]. Cash and Receivables Management - The company reported a cash balance of CNY 573.89 million at the end of the period, down from CNY 1.69 billion at the beginning of the period[144]. - Bank deposits decreased from CNY 161.35 million to CNY 108.77 million, while total cash and cash equivalents fell from CNY 169.47 million to CNY 112.72 million[145]. - The accounts receivable totaled CNY 2.61 million, with a 100% provision for bad debts on several accounts due to expected uncollectibility[148]. - The company reported a total of CNY 3.95 million in restricted cash due to pledges and freezes[145]. - The company has a total of CNY 1.43 million in performance guarantees, down from CNY 5.59 million at the beginning of the period[145]. - The company is subject to various tax rates, including a 13%, 6%, or 3% VAT depending on the service provided[161].

注：①表中非经营性占用部分，关联方范围依照《股票上市规则》确定。 ②无控股股东、实际控制人的公司，存在第一大股东或第一大股东关联人非经营性占用资金的，也应填写本表非经营性占用部分。 法定代表人：杨殿中 主管会计工作负责人：王文长 会计机构负责人：张韬 国新健康保障服务集团股份有限公司 2023 年上半年非经营性资金占用及其他关联资金往来情况汇总表 单位：人民币万元 | | | 占用方与上市公 | 上市公司 | 2023 年期初 | 2023 年上半 年占用累计发 | 2023 年上 半年占用 | 2023 年上 半年偿还 | 2023 年 6 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资 | 资金占用方名称 | | | 占用资金余 | | 资金的利 | | 月末占用 | | 占用性质 | | 金占用 | | 司的关联关系 | 核算的会计科目 | | 生金额 | | 累计发生 | | 原因 | | | | | | | 额 | （不含利息） | 息（如 | 金额 | 资金余额 | | | ...

一、申请综合授信概况 为满足公司日常经营和业务发展的需要，结合公司实际情况，公司拟向兴业 银行股份有限公司北京中关村西区支行申请综合授信人民币 8,000 万元。授信期 限为 12 个月。授信中如涉及保证金质押担保的融资业务，缴存的保证金为来源、 权属等合法的自有资金。 国新健康保障服务集团股份有限公司 关于向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司将根据资金需要逐笔申请提款，每次提款的额度、利率、期限、用途等 具体事宜以公司与银行签署的具体业务协议为准。 证券简称：国新健康 证券代码：000503 编号：2023-52 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2023 年 8 月 23 日召开第十一届董事会第十七次会议，审议通过《关于向银行申请综合授信 额度的议案》，具体内容如下： 二、事项审议情况 公司已于 2023 年 8 月 23 日召开第十一届董事会第十七次会议，审议通过了 《关于向银行申请综合授信额度的议案》。公司董事会授权董事长及董事长授权 的人员在办理上述业务时代表公司签署相关文件。 具体 ...

国新健康保障服务集团股份有限公司 公司无前期间发生延续到报告期的对外担保事项，无违规对外担保情况。 三、其他说明 除上述情况外，2023 年半年度公司不存在为控股股东及其他关联方垫支工资、 福利、保险、广告等期间费用和代为承担成本及其他支出的情况，也不存在将资 金直接或间接提供给控股股东及其他关联方使用情况。 基于以上情况，我们认为公司在 2023 年半年度对《通知》执行情况良好，有 效防范了控股股东及其关联方占用公司资金的行为，维护了公司资金安全；严格 控制对外担保风险，保护了公司股东，特别是中小投资者的权益。 独立董事对公司关联方资金占用和对外担保情况的 专项说明和独立意见 根据《关于规范上市公司与关联方资金往来及上市公司对外担保若干问题的 通知》（以下简称《通知》）和《国新健康保障服务集团股份有限公司章程》的有 关规定，作为国新健康保障服务集团股份有限公司（以下简称"公司"）独立董事， 我们查阅了公司提供的相关资料，基于个人独立判断的立场，现就公司 2023 年半 年度对外担保、资金占用等问题发表如下独立意见： 一、关联方资金占用情况 2023年初公司之控股股东及其他关联方占用资金余额为55,414.0 ...

证券简称：国新健康 证券代码：000503 编号：2023-50 具体内容详见同日在巨潮资讯网（网址：www.cninfo.com.cn）披露的公司 《2023 年半年度报告》和在《中国证券报》《上海证券报》《证券时报》及巨 潮资讯网（网址：www.cninfo.com.cn）披露的公司《2023 年半年度报告摘要》 （公告编号：2023-51）。 二、关于向银行申请综合授信额度的议案 为满足公司日常经营和业务发展的需要，结合公司实际情况，公司拟向兴 业银行股份有限公司北京中关村西区支行申请综合授信人民币8,000万元。授信 期限为12个月。授信中如涉及保证金质押担保的融资业务，缴存的保证金为来 源、权属等合法的自有资金。公司董事会授权董事长及董事长授权的人员在办 理上述业务时代表公司签署相关文件。 国新健康保障服务集团股份有限公司 第十一届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司(以下简称"公司")第十一届董事第 十七次会议于2023年8月11日以通讯方式发出会议通知，会议由董事长杨殿中先 ...

证券代码：000503 证券简称：国新健康 国新健康保障服务集团股份有限公司 投资者关系活动记录表 编号：2023－01 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 ☑业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （ ） | | | 新闻媒体单位：中国证券报，上海证券报，证券时报，证券日报， | | | 全景网，新华网，界面新闻，财经网，证券导报，网易财经，和讯， | | | 华夏时报，博览财经，财联社，经济观察报，经济日报，津云·北方 | | | 网，中国新闻网，新浪财经，腾讯财经，中国网，澎湃财经，搜狐财 | | | 经； | | | 机构及个人投资者：中国国际金融股份有限公司，于钟海、胡安 | | | 琪、万心怡；中邮基金，杨园园；中邮人寿保险股份有限公司，朱战 | | | 宇；中国铁建投资集团有限公司，谢恺；中国银河证券，孟熙、吴砚 | | | 靖、程培；中信建投证券，金戈、邹子尧；中信证券，潘儒琛；国寿 | | 参与单位名称及 | 资产，赵花荣；中翔资本，潘宇然；首创证券，翟炜、邓睿祺 ...

证券简称：国新健康 证券代码：000503 编号：2023-34 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 (参会报名二维码) 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日在巨潮资讯网（http://www.cninfo.com.cn）披露了《2022 年年度报告》及其 摘要。为使投资者及时了解公司经营情况，公司将于 2023 年 5 月 18 日（星期 四）下午 15:00 至 16:00 通过电话会议方式举行 2022 年度业绩说明会。电话会 议拨入方式如下，请扫描下方二维码报名参会： | 地点 | | 会议拨入号码 | | --- | --- | --- | | 中国内地 | | 400 810 8228 / +86 1058084199 | | 中国香港 | | +852 30051355 | | 参会密码: | 12873957 | | 出席本次说明会的公司人员有：党委副书记、董事、总经理李永华先生，独 立董事王秀丽女士，党委委员、副总经理袁洪泉先生，党委委员、总会计师王文 长先生，董事会秘 ...

Financial Performance - The company reported a total revenue of RMB 1,500,000 from the procurement of hardware and software services under the health assistance project with the Li Chuan Health Bureau[35]. - The company's operating revenue for 2022 was ¥311,079,455.60, representing a 23.19% increase from ¥252,515,004.56 in 2021[162]. - The net profit attributable to shareholders for 2022 was -¥84,471,751.01, a 51.96% improvement compared to -¥175,821,833.40 in 2021[162]. - The cash flow from operating activities for 2022 was -¥160,204,210.35, which is a 52.84% decline from -¥104,821,324.48 in 2021[162]. - The total assets at the end of 2022 were ¥1,104,696,713.12, down 7.35% from ¥1,192,309,580.42 at the end of 2021[162]. - The net assets attributable to shareholders decreased by 9.45% to ¥711,368,370.48 at the end of 2022 from ¥785,613,339.24 at the end of 2021[162]. - The basic earnings per share for 2022 improved to -¥0.0931, a 52.31% increase from -¥0.1952 in 2021[162]. - The company reported a significant reduction in non-recurring losses, with a total of ¥33,340,289.65 in non-recurring gains for 2022 compared to ¥13,493,588.30 in 2021[165]. - The company received government subsidies amounting to ¥950,254.35 in 2022, up from ¥536,998.98 in 2021[165]. Shareholder Information - The actual payment amount for the remuneration of directors, supervisors, and senior management during the reporting period was 10.6249 million yuan[1]. - The total number of shares decreased from 907,215,204 to 906,413,204, reflecting a reduction of 802,000 shares[39]. - The company’s limited shares decreased from 8,393,000 (0.93%) to 7,591,000 (0.84%) due to the reduction in holdings[39]. - The company has a total of 72 middle and senior management personnel and core employees, with a total of 8,393,000 shares granted under the incentive plan[67]. - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 26.00% of the shares, totaling 235,702,593 shares[91]. - The total number of common shareholders at the end of the reporting period was 58,456, an increase from 57,745 at the end of the previous month[87]. - The company has committed to not reducing its holdings in the newly issued shares for a period of six months following the completion of the private placement, which is expected to enhance shareholder confidence[1]. - The company has confirmed that the funds used for the subscription of the new shares will come entirely from legal self-owned or self-raised funds, ensuring no structured financing arrangements are involved[1]. - The company has stated that there are no plans to provide financial assistance or guarantees to investors participating in the private placement, maintaining compliance with regulatory requirements[1]. Corporate Governance - There were no significant internal control deficiencies identified during the reporting period, ensuring the protection of the interests of the company and all shareholders[8]. - The company has completed the election of the board of directors and supervisory board, appointing senior management during the reporting period[32]. - The company’s board and supervisory board have undergone re-election to ensure effective decision-making[129]. - The company’s financial report has been confirmed as true, accurate, and complete by its responsible persons[135]. - The company has not reported any changes in accounting policies or significant accounting errors during the reporting period, ensuring the integrity of its financial statements[41]. Regulatory Compliance - The company did not receive any administrative penalties due to environmental issues during the reporting period[12]. - The company has committed to strictly adhering to regulatory guidelines and maintaining transparency in its operations, which is crucial for investor trust[1]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[21]. - The company has not faced any penalties or rectification issues during the reporting period[132]. - The company has no financial transactions with related financial companies during the reporting period[121]. Business Operations - The company’s strategic focus includes high-tech product development, sales, and consulting services, as well as investment consulting and real estate development[73]. - The company focuses on four main business segments: digital medical insurance, digital healthcare, digital pharmaceuticals, and health services[181]. - The digital medical insurance segment aims to support the reform of medical insurance payment methods and improve the efficiency of medical fund usage[181]. - The company has implemented a DRG (Diagnosis-Related Group) payment service, enhancing the management of medical insurance funds and promoting quality-based payment systems[181]. - The introduction of big data and AI technologies has improved the efficiency of medical fund monitoring and fraud detection[189]. - The company is committed to building a comprehensive medical insurance credit supervision system, enhancing the regulatory environment for medical insurance[190]. - The national policies, including the "Data Twenty Articles," provide new opportunities for the company's business development and strategic planning[180]. - The company aims to become a leader in digital medical insurance and a builder of digital healthcare and pharmaceuticals[183]. - The company is focused on sustainable business development, leveraging data value and innovative mechanisms[183]. Related Party Transactions - The company has engaged in related party transactions with its wholly-owned subsidiary Guoxin Limited, as disclosed in previous announcements[79]. - The company reported no significant related party transactions during the reporting period[96]. - The company has a non-operating related party debt of 164.24 million RMB, with no new additions or repayments during the reporting period[120]. - The company has maintained a stable interest rate of 0.00% on related party debts[120]. Stock Repurchase - A total of 802,000 restricted stocks were repurchased and canceled due to the disqualification of 7 incentive objects from the stock incentive plan[5]. - The company repurchased 802,000 shares, which represents 0.09% of the total share capital, for a total amount of approximately 40.58 million RMB[76]. - The company’s stock repurchase plan is aimed at canceling shares to enhance shareholder value and does not affect the control structure of the company[86]. - The actual controller of the company remains unchanged after the stock repurchase, with China Guoxin Holdings Co., Ltd. continuing as the actual controller[86]. - There were no major contracts or leasing situations during the reporting period[97][98].

Financial Performance - Total operating revenue for Q1 2023 was ¥55,766,199.77, an increase of 47.0% compared to ¥37,951,381.37 in Q1 2022[11] - Total operating costs for Q1 2023 were ¥99,793,458.91, up 23.5% from ¥80,759,723.77 in the same period last year[11] - The company reported a net loss of ¥43,123,912.80 for Q1 2023, an improvement from a net loss of ¥49,421,999.82 in Q1 2022[11] - The net profit for the current period is -43,866,780.96, compared to -49,422,023.57 in the previous period, showing an improvement[14] - The total comprehensive income for the current period is -44,125,283.59, compared to -49,442,066.65 in the previous period[14] - Basic and diluted earnings per share are both -0.0484, an improvement from -0.0545 in the previous period[14] - Net loss attributable to shareholders was ¥-43,865,115.01, improving by 11.25% from ¥-49,423,957.16 year-over-year[27] Cash Flow and Liquidity - Cash and cash equivalents decreased to ¥116,974,970.15 from ¥169,465,147.63 at the beginning of the year, a decline of 30.9%[3] - The net cash flow from operating activities is -83,500,999.68, an improvement from -101,791,799.62 in the previous period[19] - Cash inflows from operating activities totaled 48,705,936.60, up from 23,618,915.13 in the previous period[19] - Cash outflows from operating activities increased to 132,206,936.28 from 125,410,714.75 in the previous period[19] - The ending cash and cash equivalents balance is 112,821,001.03, down from 238,032,127.40 in the previous period[21] Assets and Liabilities - Total assets decreased to ¥1,063,525,048.13 from ¥1,104,696,713.12, a reduction of 3.7%[10] - Total liabilities increased slightly to ¥393,847,260.24 from ¥391,707,776.39, reflecting a 0.5% rise[7] - The company’s equity attributable to shareholders decreased to ¥668,058,887.59 from ¥711,368,370.48, a decline of 6.1%[7] - Total assets at the end of the reporting period were ¥1,063,525,048.13, a decrease of 3.73% from ¥1,104,696,713.12 at the end of the previous year[27] Research and Development - Research and development expenses for Q1 2023 were ¥967,945.83, down 52.5% from ¥2,042,652.21 in Q1 2022[11] - Research and development expenses decreased by 52.61% to ¥967,945.83, reflecting differences in project stages[32] Market Strategy and Future Plans - The company plans to focus on market expansion and new product development in the upcoming quarters[12] - Sales expenses increased by 77.33% to ¥8,515,293.56, driven by enhanced market expansion efforts[32] Shareholder Information - The total number of common shareholders at the end of the reporting period is 57,745, with the largest shareholder, China Oceanwide Holdings, holding 26.00% of shares, equating to 235,702,593 shares[37] - The second largest shareholder, Jiao Yu, holds 1.03% of shares, amounting to 9,299,444 shares, while Hong Kong Central Clearing Limited holds 1.02% with 9,256,810 shares[37] Investments and Financing - The company experienced a 100% increase in short-term borrowings, totaling ¥90,113,307.28, due to new bank credit loans[32] - The net cash flow from financing activities is 43,866,996.67, compared to -715,521.65 in the previous period[21] - The company received government subsidies amounting to ¥312,113.78, primarily due to personal income tax refunds[29] - Investment income was reported at ¥335,268.91, a significant turnaround from a loss of ¥-537,717.96 in the previous year, due to profit recognition from equity method accounting[32] Contractual Adjustments - A contract adjustment was made for a software development project, reducing the total price from RMB 13,082,300 to RMB 12,432,300[43] - The company has decided to waive its preemptive rights for capital increase in its associate company, Beijing Yiyong Technology Co., Ltd.[44]